Neogenomics (NEO) Change in Receivables (2010 - 2026)

Neogenomics has reported Change in Receivables for 17 years, with the latest figure at $8.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 1124.85% year-over-year to $8.2 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (up 25.28% YoY), and the FY2025 full-year result was $6.2 million, down 68.01% from the prior year.
• Change in Receivables for Q1 2026 stood at $8.2 million, up from $4.2 million in the prior quarter.
• The five-year high for Change in Receivables was $9.1 million in Q1 2024, with the low at -$1.4 million in Q4 2023.
• Historically, Change in Receivables has averaged $3.1 million across 5 years, with a median of $2.4 million in 2025.
• The largest YoY upside for Change in Receivables was 1271.46% in 2023 against a maximum downside of 118.3% in 2023.
• Neogenomics' Change in Receivables stood at $7.7 million in 2022, then sank by 118.3% to -$1.4 million in 2023, then surged by 37.11% to -$888000.0 in 2024, then jumped by 573.76% to $4.2 million in 2025, then jumped by 94.49% to $8.2 million in 2026.
• The last three Change in Receivables figures came in at $8.2 million (Q1 2026), $4.2 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.